Methanobactin reverses acute liver failure in a rat model of Wilson disease

Lichtmannegger J., Leitzinger C., Wimmer R., Schmitt S., Schulz S., Kabiri Y., Eberhagen C., Rieder T., Janik D., Neff F., Straub B., Schirmacher P., Di Spirito A., Bandow N., Baral B., Flatley A., Kremmer E., Denk G., Reiter F., Hohenester S., Eckardt-Schupp F., Dencher N., Adamski J., Sauer V., Niemietz C., Schmidt H., Merle U., Gotthardt D., Kroemer G., Weiss K., Zischka H.

Abstract

In Wilson disease (WD), functional loss of ATPase copper-transporting β (ATP7B) impairs biliary copper excretion, leading to excessive copper accumulation in the liver and fulminant hepatitis. Current US Food and Drug Administration-and European Medicines Agency-approved pharmacological treatments usually fail to restore copper homeostasis in patients with WD who have progressed to acute liver failure, leaving liver transplantation as the only viable treatment option. Here, we investigated the therapeutic utility of methanobactin (MB), a peptide produced by Methylosinus trichosporium OB3b, which has an exceptionally high affinity for copper. We demonstrated that ATP7B-deficient rats recapitulate WD-associated phenotypes, including hepatic copper accumulation, liver damage, and mitochondrial impairment. Short-term treatment of these rats with MB efficiently reversed mitochondrial impairment and liver damage in the acute stages of liver copper accumulation compared with that seen in untreated ATP7B-deficient rats. This beneficial effect was associated with depletion of copper from hepatocyte mitochondria. Moreover, MB treatment prevented hepatocyte death, subsequent liver failure, and death in the rodent model. These results suggest that MB has potential as a therapeutic agent for the treatment of acute WD.